Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.53 |
| ▸ | DHODH | Q02127 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | SMYD3 | Q9H7B4 | 4/20 | 0.44 |
| ▸ | SUV39H2 | Q9H5I1 | 3/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | KHK | P50053 | 2/20 | 0.42 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14513 | 0.81 | RIPK1 (0.46) | RIPK1DHODHHDAC4HDAC6SMYD3 | |
| SCHEMBL14512 | 0.76 | RIPK1 (0.41) | RIPK1DHODHHDAC4HDAC6SMYD3 | |
| SCHEMBL14507 | 0.75 | RIPK1 (0.39) | RIPK1DHODHHDAC4HDAC6SMYD3 | |
| SCHEMBL13865 | 0.75 | RIPK1 (0.40) | RIPK1DHODHHDAC4HDAC6SMYD3 | |
| SCHEMBL14436 | 0.74 | RIPK1 (0.39) | RIPK1DHODHHDAC4HDAC6SMYD3 | |
| SCHEMBL14232 | 0.73 | RIPK1 (0.39) | RIPK1DHODHHDAC4HDAC6SMYD3 | |
| SCHEMBL14514 | 0.73 | RIPK1 (0.37) | RIPK1DHODHHDAC4HDAC6SMYD3 | |
| SCHEMBL14330 | 0.73 | RIPK1 (0.38) | RIPK1DHODHHDAC4HDAC6SMYD3 | |
| SCHEMBL13886 | 0.72 | ADORA2A (0.49) | — | |
| SCHEMBL15219421 | 0.69 | KDM5A (0.51) | HDAC4HDAC6SMYD3KHKHPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160031893-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2016-02-04 | — | — | US | disclosed |
| US-9193731-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-9193731-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20120220566-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120220566-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| WO-2011047319-A2 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220566-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | MPO, LPO, CAT | RIPK1 2895/4885DHODH 516/4885HDAC4 2407/4885 |
| US-20160031893-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MPO, LPO, CAT | RIPK1 2895/4885DHODH 516/4885HDAC4 2407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.